Clinical and multi-omics study on aggressive NK cell leukemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024444

Enrollment

Unknown

Registered

2019-07-12

Start date

2019-07-31

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aggressive NK cell leukemia

Interventions

single arm:chemotherapy+Ruxolitinib

Eligibility

Sex/Gender

All

Age

14 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) patients diagnosed with aggressive NK cell leukemia; (2) aged 14-70 years; (3) ECOG score 0-3; (4) patients with the capacity to understand this study and voluntary informed consent is given.

Exclusion criteria

Exclusion criteria: (1) accompanied with other advanced cancer; (2) patients with severe underlying disease which can't tolerate chemotherapy; (3) cardiac dysfunction:ejection fraction(EF)<30%, cardiac dysfunction above grade III; (4) refuse to attend this study.

Design outcomes

Primary

Measure	Time frame
survival time;	—

Countries

China

Contacts

Public ContactSuning Chen

The First Affiliated Hospital of Soochow University

chensuning@sina.com+86 13814881746

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026